Skip to main content
OpenTrials
Completed

NCT Number: NCT01578018

Tumor Markers in Lung Cancer: DCAMLK-1LK-1

DCAMLK1 is a Ca2+ - ca/modulin (CaM) - dependent protein kinase that is a marker of stem cells in colonic crypts. Mutations within the stem cell population are thought to be responsible for the development of most colorectal carcinomas and studies have shown that DCAMLK1 is highly expressed in these tumors. Since the lung is an embryological development of the foregut, the investigators speculate that DCAMLK1 will also be upregulated in lung cancers.

The aim of this pilot study is to measure DCAMLK1 levels in the blood of patients with suspected malignant and benign lung diseases, and to correlate DCAMKL1 levels with smoking status.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Lung Cancer Behavior Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Smoking Thoracic Neoplasms

Age range

45 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

VAMC-OKC

Oklahoma City, Oklahoma, 73104, United States

About this study

In the investigators' preliminary study DCAMKL1 antigen was detected not only in malignant tissue, but also in BAL fluid from patients with benign lung disease. This suggests that DCAMKL1 expression might be induced by smoking or benign lung diseases. To examine this hypothesis, the investigators will compare DCAMLK1 expression in blood from patients with lung cancer to controls who are current or former smokers with benign lung disease.

Previous work has showed that DCAMLK1 is not detectable in the blood of healthy non smoking individuals. To determine whether smoking and or pulmonary inflammation induce DCAMLK1 expression, the investigators will obtain serum samples from 20 control patients with lung disease who are seen in the Chest Clinic at the Oklahoma City VAMC. Smoking histories will be obtained for all participants and DCAMLK1 levels will be correlated with smoking status.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • >45 years of age

Exclusion criteria

  • Unable to provide informed consent

Treatment and study plan

Measure DCAM levels in blood

Other

Measure DCAM levels in blood

Other names: Lung Cancer

DCAM levels in blood

Other

DCAM levels in blood

Other names: Lung Disease

Primary outcomes

  1. Tumor Markers in Lung Cancer:

    Time frame: 6 months

    DCAMLK-1LK-1 levels will be measured in the blood of patients with Lung Cancer and compared to that of controls with other lung diseases.

Sponsors and collaborators

Lead sponsor

University of Oklahoma

Other

Registry information

Official study title

Tumor Markers in Lung Cancer: DCAMLK-1LK-1: A Pilot Study

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Apr 16, 2012
Registry last updated
Aug 10, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.